Gilead Sciences Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
156 / 1361
Position in country
2776 / 14179
Return on Assets, %
9
-40.3
Net income margin, %
19.9
-180
EBITDA margin, %
37.9
-168.2
Debt to Equity, %
109.4
3.2
Intangible assets and goodwill, %
55.9
0.2
Revenue CAGR 3Y, %
3.1
12.5
Total Equity change 1Y, %
7.5
-9
Revenue Y, % chg
-0.7
0
P/E
15.1
31
P/BV
3.7
1.8
P/S
3.1
10.3
EV/S
3.7
7.5
EV/EBITDA
8.9
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
17.5
131.1
Forward P/E
9.9
21.4
Dividend Yield, %
4.4
1.1
Forward Dividend Yield, %
4.6
0.1
Expected dividend per share
3.1
0
Payout Ratio, %
67.3
0
Dividend Ex Date
2024-03-14
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Biomarin Pharmaceutical Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
84881.2
Ticker
GILD.O
ISIN
US3755581036
IPO date
1992-01-22
Availability on Russian exchanges
Yes
Reporting for
2024-02-23
Date fact. publication of reports
2023-12-31
Company Description
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: